25 XP   0   0   10

Medigene AG
Buy, Hold or Sell?

Let's analyse Medigene together

PenkeI guess you are interested in Medigene AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Medigene AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Medigene AG

I send you an email if I find something interesting about Medigene AG.

Quick analysis of Medigene (30 sec.)










What can you expect buying and holding a share of Medigene? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.81
Expected worth in 1 year
€0.20
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
€-0.62
Return On Investment
-50.6%

For what price can you sell your share?

Current Price per Share
€1.22
Expected price per share
€0 - €1.91
How sure are you?
50%

1. Valuation of Medigene (5 min.)




Live pricePrice per Share (EOD)

€1.22

Intrinsic Value Per Share

€-8.17 - €-5.05

Total Value Per Share

€-7.35 - €-4.24

2. Growth of Medigene (5 min.)




Is Medigene growing?

Current yearPrevious yearGrowGrow %
How rich?$22.8m$48.2m-$18.6m-62.8%

How much money is Medigene making?

Current yearPrevious yearGrowGrow %
Making money-$5.7m-$5.2m-$515.1k-8.9%
Net Profit Margin-277.3%-195.3%--

How much money comes from the company's main activities?

3. Financial Health of Medigene (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#562 / 996

Most Revenue
#441 / 996

Most Profit
#473 / 996

Most Efficient
#633 / 996

What can you expect buying and holding a share of Medigene? (5 min.)

Welcome investor! Medigene's management wants to use your money to grow the business. In return you get a share of Medigene.

What can you expect buying and holding a share of Medigene?

First you should know what it really means to hold a share of Medigene. And how you can make/lose money.

Speculation

The Price per Share of Medigene is €1.22. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Medigene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Medigene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.81. Based on the TTM, the Book Value Change Per Share is €-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Medigene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.39-31.7%-0.22-18.4%-0.19-15.2%-0.20-16.7%-0.16-13.4%
Usd Book Value Change Per Share0.000.0%-0.17-13.7%-0.08-6.7%-0.18-14.8%-0.02-1.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-0.17-13.7%-0.08-6.7%-0.18-14.8%-0.02-1.3%
Usd Price Per Share1.65-1.91-2.65-4.01-6.92-
Price to Earnings Ratio-1.07--2.51--1.42-39.95-6.45-
Price-to-Total Gains Ratio-6.03-0.82--15.37--57.48-
Price to Book Ratio1.87-1.74-1.46-1.70-2.44-
Price-to-Total Gains Ratio-6.03-0.82--15.37--57.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.3237
Number of shares755
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.17-0.18
Usd Total Gains Per Share-0.17-0.18
Gains per Quarter (755 shares)-126.37-136.75
Gains per Year (755 shares)-505.48-547.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-505-5150-547-557
20-1011-10200-1094-1104
30-1516-15250-1641-1651
40-2022-20300-2188-2198
50-2527-25350-2735-2745
60-3033-30400-3282-3292
70-3538-35450-3829-3839
80-4044-40500-4376-4386
90-4549-45550-4923-4933
100-5055-50600-5470-5480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%3.037.00.07.5%6.054.00.010.0%
Book Value Change Per Share0.02.02.00.0%1.05.06.08.3%1.011.08.05.0%8.024.08.020.0%13.036.011.021.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.060.00.0%
Total Gains per Share0.02.02.00.0%1.05.06.08.3%1.011.08.05.0%8.024.08.020.0%13.036.011.021.7%

Fundamentals of Medigene

About Medigene AG

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Fundamental data was last updated by Penke on 2024-05-17 22:55:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Medigene AG.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Medigene earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Medigene to the Biotechnology industry mean.
  • A Net Profit Margin of -310.0% means that €-3.10 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Medigene AG:

  • The MRQ is -310.0%. The company is making a huge loss. -2
  • The TTM is -277.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-310.0%TTM-277.3%-32.7%
TTM-277.3%YOY-195.3%-82.0%
TTM-277.3%5Y-191.6%-85.7%
5Y-191.6%10Y-205.6%+14.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-310.0%-177.0%-133.0%
TTM-277.3%-223.7%-53.6%
YOY-195.3%-256.7%+61.4%
5Y-191.6%-431.4%+239.8%
10Y-205.6%-551.3%+345.7%
1.1.2. Return on Assets

Shows how efficient Medigene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Medigene to the Biotechnology industry mean.
  • -29.0% Return on Assets means that Medigene generated €-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Medigene AG:

  • The MRQ is -29.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.0%TTM-15.0%-14.1%
TTM-15.0%YOY-10.1%-4.9%
TTM-15.0%5Y-8.2%-6.8%
5Y-8.2%10Y-5.5%-2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.0%-11.9%-17.1%
TTM-15.0%-11.7%-3.3%
YOY-10.1%-10.8%+0.7%
5Y-8.2%-13.0%+4.8%
10Y-5.5%-14.2%+8.7%
1.1.3. Return on Equity

Shows how efficient Medigene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Medigene to the Biotechnology industry mean.
  • -43.7% Return on Equity means Medigene generated €-0.44 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Medigene AG:

  • The MRQ is -43.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-43.7%TTM-22.1%-21.6%
TTM-22.1%YOY-14.4%-7.7%
TTM-22.1%5Y-11.6%-10.5%
5Y-11.6%10Y-7.8%-3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-43.7%-15.1%-28.6%
TTM-22.1%-14.7%-7.4%
YOY-14.4%-13.3%-1.1%
5Y-11.6%-17.6%+6.0%
10Y-7.8%-19.1%+11.3%

1.2. Operating Efficiency of Medigene AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Medigene is operating .

  • Measures how much profit Medigene makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Medigene to the Biotechnology industry mean.
  • An Operating Margin of -306.6% means the company generated €-3.07  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Medigene AG:

  • The MRQ is -306.6%. The company is operating very inefficient. -2
  • The TTM is -277.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-306.6%TTM-277.1%-29.5%
TTM-277.1%YOY-123.3%-153.8%
TTM-277.1%5Y-187.1%-90.0%
5Y-187.1%10Y-193.2%+6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-306.6%-348.2%+41.6%
TTM-277.1%-232.7%-44.4%
YOY-123.3%-266.9%+143.6%
5Y-187.1%-412.2%+225.1%
10Y-193.2%-516.7%+323.5%
1.2.2. Operating Ratio

Measures how efficient Medigene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.07 means that the operating costs are €4.07 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Medigene AG:

  • The MRQ is 4.066. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.773. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.066TTM3.773+0.293
TTM3.773YOY2.920+0.853
TTM3.7735Y2.312+1.461
5Y2.31210Y2.796-0.483
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0663.097+0.969
TTM3.7733.332+0.441
YOY2.9203.564-0.644
5Y2.3125.224-2.912
10Y2.7966.637-3.841

1.3. Liquidity of Medigene AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Medigene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.53 means the company has €2.53 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Medigene AG:

  • The MRQ is 2.526. The company is able to pay all its short-term debts. +1
  • The TTM is 2.449. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.526TTM2.449+0.077
TTM2.449YOY4.021-1.572
TTM2.4495Y3.459-1.010
5Y3.45910Y4.509-1.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5263.798-1.272
TTM2.4494.146-1.697
YOY4.0215.212-1.191
5Y3.4596.093-2.634
10Y4.5096.441-1.932
1.3.2. Quick Ratio

Measures if Medigene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Medigene to the Biotechnology industry mean.
  • A Quick Ratio of 3.58 means the company can pay off €3.58 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Medigene AG:

  • The MRQ is 3.581. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.869. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.581TTM2.869+0.713
TTM2.869YOY4.270-1.402
TTM2.8695Y3.945-1.076
5Y3.94510Y5.261-1.316
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5813.165+0.416
TTM2.8693.776-0.907
YOY4.2705.140-0.870
5Y3.9455.839-1.894
10Y5.2616.367-1.106

1.4. Solvency of Medigene AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Medigene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Medigene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.34 means that Medigene assets are financed with 33.6% credit (debt) and the remaining percentage (100% - 33.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Medigene AG:

  • The MRQ is 0.336. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.310. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.336TTM0.310+0.026
TTM0.310YOY0.260+0.050
TTM0.3105Y0.268+0.042
5Y0.26810Y0.262+0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3360.340-0.004
TTM0.3100.341-0.031
YOY0.2600.279-0.019
5Y0.2680.366-0.098
10Y0.2620.380-0.118
1.4.2. Debt to Equity Ratio

Measures if Medigene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Medigene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 50.6% means that company has €0.51 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Medigene AG:

  • The MRQ is 0.506. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.451. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.506TTM0.451+0.055
TTM0.451YOY0.353+0.098
TTM0.4515Y0.369+0.082
5Y0.36910Y0.360+0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5060.388+0.118
TTM0.4510.415+0.036
YOY0.3530.356-0.003
5Y0.3690.443-0.074
10Y0.3600.469-0.109

2. Market Valuation of Medigene AG

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Medigene generates.

  • Above 15 is considered overpriced but always compare Medigene to the Biotechnology industry mean.
  • A PE ratio of -1.07 means the investor is paying €-1.07 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Medigene AG:

  • The EOD is -0.857. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.071. Based on the earnings, the company is expensive. -2
  • The TTM is -2.511. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.857MRQ-1.071+0.214
MRQ-1.071TTM-2.511+1.440
TTM-2.511YOY-1.422-1.089
TTM-2.5115Y39.954-42.465
5Y39.95410Y6.450+33.503
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.857-2.289+1.432
MRQ-1.071-2.558+1.487
TTM-2.511-2.723+0.212
YOY-1.422-3.900+2.478
5Y39.954-6.368+46.322
10Y6.450-6.544+12.994
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Medigene AG:

  • The EOD is -1.080. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.350. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.190. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.080MRQ-1.350+0.270
MRQ-1.350TTM-2.190+0.840
TTM-2.190YOY-0.644-1.546
TTM-2.1905Y-4.042+1.852
5Y-4.04210Y-8.558+4.516
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.080-3.247+2.167
MRQ-1.350-3.308+1.958
TTM-2.190-3.522+1.332
YOY-0.644-5.154+4.510
5Y-4.042-8.005+3.963
10Y-8.558-8.608+0.050
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Medigene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.87 means the investor is paying €1.87 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Medigene AG:

  • The EOD is 1.498. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.872. Based on the equity, the company is underpriced. +1
  • The TTM is 1.738. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.498MRQ1.872-0.374
MRQ1.872TTM1.738+0.135
TTM1.738YOY1.457+0.281
TTM1.7385Y1.705+0.033
5Y1.70510Y2.444-0.739
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4981.996-0.498
MRQ1.8722.027-0.155
TTM1.7382.073-0.335
YOY1.4572.696-1.239
5Y1.7053.727-2.022
10Y2.4444.109-1.665
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Medigene AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.1540%-0.0750%-0.1670%-0.0150%
Book Value Per Share--0.8141.057-23%1.721-53%2.163-62%2.566-68%
Current Ratio--2.5262.449+3%4.021-37%3.459-27%4.509-44%
Debt To Asset Ratio--0.3360.310+8%0.260+29%0.268+25%0.262+28%
Debt To Equity Ratio--0.5060.451+12%0.353+43%0.369+37%0.360+40%
Dividend Per Share----0%-0%-0%-0%
Eps---0.356-0.206-42%-0.171-52%-0.188-47%-0.151-58%
Free Cash Flow Per Share---0.282-0.229-19%0.077-468%-0.135-52%-0.125-56%
Free Cash Flow To Equity Per Share---0.306-0.240-22%0.074-514%-0.141-54%-0.020-93%
Gross Profit Margin--1.0011.001+0%1.015-1%-0.346+135%0.587+70%
Intrinsic Value_10Y_max---5.050--------
Intrinsic Value_10Y_min---8.168--------
Intrinsic Value_1Y_max---0.367--------
Intrinsic Value_1Y_min---0.558--------
Intrinsic Value_3Y_max---1.209--------
Intrinsic Value_3Y_min---1.912--------
Intrinsic Value_5Y_max---2.178--------
Intrinsic Value_5Y_min---3.514--------
Market Cap31556520.000-25%39445650.00045588825.000-13%63210037.500-38%95625308.700-59%164954595.150-76%
Net Profit Margin---3.100-2.773-11%-1.953-37%-1.916-38%-2.056-34%
Operating Margin---3.066-2.771-10%-1.233-60%-1.871-39%-1.932-37%
Operating Ratio--4.0663.773+8%2.920+39%2.312+76%2.796+45%
Pb Ratio1.498-25%1.8721.738+8%1.457+29%1.705+10%2.444-23%
Pe Ratio-0.857+20%-1.071-2.511+134%-1.422+33%39.954-103%6.450-117%
Price Per Share1.220-25%1.5251.763-13%2.444-38%3.697-59%6.377-76%
Price To Free Cash Flow Ratio-1.080+20%-1.350-2.190+62%-0.644-52%-4.042+199%-8.558+534%
Quick Ratio--3.5812.869+25%4.270-16%3.945-9%5.261-32%
Return On Assets---0.290-0.150-48%-0.101-65%-0.082-72%-0.055-81%
Return On Equity---0.437-0.221-49%-0.144-67%-0.116-73%-0.078-82%
Total Gains Per Share----0.1540%-0.0750%-0.1670%-0.0150%
Usd Book Value--22856610.00029660373.750-23%48285755.000-53%60699185.750-62%72020347.000-68%
Usd Book Value Change Per Share----0.1670%-0.0820%-0.1810%-0.0160%
Usd Book Value Per Share--0.8841.147-23%1.867-53%2.347-62%2.784-68%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.386-0.224-42%-0.185-52%-0.204-47%-0.164-58%
Usd Free Cash Flow---7924840.000-6421708.125-19%2154674.375-468%-3421927.250-57%-3335398.500-58%
Usd Free Cash Flow Per Share---0.306-0.248-19%0.083-468%-0.147-52%-0.136-56%
Usd Free Cash Flow To Equity Per Share---0.332-0.260-22%0.080-514%-0.153-54%-0.022-93%
Usd Market Cap34238824.200-25%42798530.25049463875.125-13%68582890.688-38%103753459.940-59%178975735.738-76%
Usd Price Per Share1.324-25%1.6551.912-13%2.651-38%4.011-59%6.919-76%
Usd Profit---9989595.000-5792136.875-42%-5277033.125-47%-5404710.500-46%-4299231.125-57%
Usd Revenue--3222450.0002044411.250+58%9284480.625-65%3282640.375-2%2749674.813+17%
Usd Total Gains Per Share----0.1670%-0.0820%-0.1810%-0.0160%
 EOD+2 -5MRQTTM+5 -24YOY+2 -275Y+3 -2610Y+5 -24

3.2. Fundamental Score

Let's check the fundamental score of Medigene AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.857
Price to Book Ratio (EOD)Between0-11.498
Net Profit Margin (MRQ)Greater than0-3.100
Operating Margin (MRQ)Greater than0-3.066
Quick Ratio (MRQ)Greater than13.581
Current Ratio (MRQ)Greater than12.526
Debt to Asset Ratio (MRQ)Less than10.336
Debt to Equity Ratio (MRQ)Less than10.506
Return on Equity (MRQ)Greater than0.15-0.437
Return on Assets (MRQ)Greater than0.05-0.290
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Medigene AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.763
Ma 20Greater thanMa 501.427
Ma 50Greater thanMa 1001.745
Ma 100Greater thanMa 2001.620
OpenGreater thanClose1.230
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Other Income Expense Net -99-64-16324-13981-59272213



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets31,716
Total Liabilities10,650
Total Stockholder Equity21,066
 As reported
Total Liabilities 10,650
Total Stockholder Equity+ 21,066
Total Assets = 31,716

Assets

Total Assets31,716
Total Current Assets18,137
Long-term Assets13,579
Total Current Assets
Cash And Cash Equivalents 8,674
Short-term Investments 8,000
Net Receivables 1,035
Inventory 0
Other Current Assets 428
Total Current Assets  (as reported)18,137
Total Current Assets  (calculated)18,137
+/-0
Long-term Assets
Property Plant Equipment 3,438
Intangible Assets 9,853
Long-term Assets Other 288
Long-term Assets  (as reported)13,579
Long-term Assets  (calculated)13,579
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,179
Long-term Liabilities3,471
Total Stockholder Equity21,066
Total Current Liabilities
Short-term Debt 914
Accounts payable 340
Other Current Liabilities 2,729
Total Current Liabilities  (as reported)7,179
Total Current Liabilities  (calculated)3,983
+/- 3,196
Long-term Liabilities
Long-term Liabilities  (as reported)3,471
Long-term Liabilities  (calculated)0
+/- 3,471
Total Stockholder Equity
Common Stock24,563
Retained Earnings -486,190
Accumulated Other Comprehensive Income 2,448
Other Stockholders Equity 480,245
Total Stockholder Equity (as reported)21,066
Total Stockholder Equity (calculated)21,066
+/-0
Other
Cash and Short Term Investments 16,674
Common Stock Shares Outstanding 25,866
Current Deferred Revenue3,196
Liabilities and Stockholders Equity 31,716
Net Debt -5,724
Net Working Capital 10,958
Short Long Term Debt Total 2,950



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
65,723
62,922
66,166
66,902
58,201
66,389
60,407
60,392
53,292
49,545
64,634
62,275
61,255
58,265
57,153
54,077
52,655
58,747
57,175
69,203
71,283
69,728
74,656
115,730
113,531
110,095
105,599
115,175
111,715
105,837
119,823
114,877
111,937
107,862
138,637
133,991
129,590
128,218
121,604
117,386
109,215
0
93,102
0
74,750
0
66,875
0
59,470
0
76,499
51,678
51,678
0
42,177
31,716
31,716
31,71631,71642,177051,67851,67876,499059,470066,875074,750093,1020109,215117,386121,604128,218129,590133,991138,637107,862111,937114,877119,823105,837111,715115,175105,599110,095113,531115,73074,65669,72871,28369,20357,17558,74752,65554,07757,15358,26561,25562,27564,63449,54553,29260,39260,40766,38958,20166,90266,16662,92265,723000
   > Total Current Assets 
0
0
0
20,769
18,728
18,933
19,877
17,927
26,928
21,703
21,076
18,080
14,466
29,535
27,458
24,447
21,601
20,739
17,929
16,263
13,845
11,852
23,294
24,666
22,599
17,938
59,814
59,900
64,864
58,372
67,491
63,973
58,950
71,264
66,398
63,342
60,272
59,325
54,847
62,196
66,565
69,641
65,590
57,728
0
42,602
32,695
32,695
0
24,322
24,164
24,164
0
41,742
37,252
37,252
33,224
27,917
18,137
18,137
18,13718,13727,91733,22437,25237,25241,742024,16424,16424,322032,69532,69542,602057,72865,59069,64166,56562,19654,84759,32560,27263,34266,39871,26458,95063,97367,49158,37264,86459,90059,81417,93822,59924,66623,29411,85213,84516,26317,92920,73921,60124,44727,45829,53514,46618,08021,07621,70326,92817,92719,87718,93318,72820,769000
       Cash And Cash Equivalents 
0
0
0
12,251
8,181
8,200
10,782
4,770
18,801
15,860
15,378
12,811
10,122
25,376
22,243
20,113
16,676
14,960
11,655
10,166
7,221
4,097
16,689
14,976
13,145
10,059
50,768
8,759
8,310
10,672
5,599
14,630
10,045
15,871
16,374
27,724
27,104
21,839
27,329
27,408
21,547
23,256
18,514
34,682
0
19,882
0
30,033
0
22,232
0
0
0
28,383
22,224
22,224
-33,224
16,550
8,674
8,674
8,6748,67416,550-33,22422,22422,22428,38300022,232030,033019,882034,68218,51423,25621,54727,40827,32921,83927,10427,72416,37415,87110,04514,6305,59910,6728,3108,75950,76810,05913,14514,97616,6894,0977,22110,16611,65514,96016,67620,11322,24325,37610,12212,81115,37815,86018,8014,77010,7828,2008,18112,251000
       Short-term Investments 
0
0
0
0
0
636
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38,000
38,000
38,000
38,000
38,000
38,000
44,000
39,000
24,000
22,000
27,000
17,000
24,000
34,000
42,000
42,000
20,000
0
20,000
0
0
0
0
0
0
0
0
11,000
11,000
66,448
8,000
8,000
8,000
8,0008,0008,00066,44811,00011,0000000000020,000020,00042,00042,00034,00024,00017,00027,00022,00024,00039,00044,00038,00038,00038,00038,00038,00038,00000000000000000000000063600000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,175
677
1,807
610
2,699
1,373
1,592
915
787
977
623
5,076
3,046
0
2,720
1,960
1,960
0
954
1,332
1,332
0
1,075
3,240
3,371
0
1,335
416
1,035
1,0354161,33503,3713,2401,07501,3321,33295401,9601,9602,72003,0465,0766239777879151,5921,3732,6996101,8076772,1750000000000000000000000000000000
       Other Current Assets 
0
0
0
7,063
8,287
7,827
6,646
11,464
5,958
3,692
3,545
3,066
2,262
2,042
2,610
2,129
1,698
2,285
2,804
3,051
2,515
3,844
2,813
5,284
3,661
2,108
2,387
6,487
11,155
2,644
16,995
3,477
3,304
2,925
2,718
3,894
3,689
3,007
3,136
3,490
3,970
4,385
5,076
3,046
0
2,720
286
286
0
1,136
20
20
0
1,284
788
657
0
2,032
1,047
428
4281,0472,03206577881,284020201,13602862862,72003,0465,0764,3853,9703,4903,1363,0073,6893,8942,7182,9253,3043,47716,9952,64411,1556,4872,3872,1083,6615,2842,8133,8442,5153,0512,8042,2851,6982,1292,6102,0422,2623,0663,5453,6925,95811,4646,6467,8278,2877,063000
   > Long-term Assets 
0
0
0
44,954
44,194
47,233
47,025
40,274
39,461
38,704
39,316
35,212
35,079
35,099
34,817
36,808
36,664
36,414
36,148
36,392
44,902
45,323
45,909
46,617
47,129
56,718
55,916
53,631
45,231
47,227
47,684
47,742
46,887
48,559
48,479
48,595
47,590
79,312
79,144
67,394
61,653
51,963
51,796
51,487
0
50,500
0
0
0
42,552
0
0
0
34,757
14,139
14,426
-33,224
14,260
13,579
13,579
13,57913,57914,260-33,22414,42614,13934,75700042,55200050,500051,48751,79651,96361,65367,39479,14479,31247,59048,59548,47948,55946,88747,74247,68447,22745,23153,63155,91656,71847,12946,61745,90945,32344,90236,39236,14836,41436,66436,80834,81735,09935,07935,21239,31638,70439,46140,27447,02547,23344,19444,954000
       Property Plant Equipment 
0
0
0
1,063
1,000
1,074
1,005
960
983
893
946
829
848
778
710
604
531
478
423
405
390
645
922
951
926
1,539
1,685
2,502
2,717
2,777
3,397
3,323
3,378
3,918
3,835
4,329
4,418
4,167
3,985
4,261
9,306
9,265
8,900
8,824
0
8,065
6,882
6,882
0
5,856
4,904
4,904
0
4,366
4,392
4,392
0
3,997
3,438
3,438
3,4383,4383,99704,3924,3924,36604,9044,9045,85606,8826,8828,06508,8248,9009,2659,3064,2613,9854,1674,4184,3293,8353,9183,3783,3233,3972,7772,7172,5021,6851,5399269519226453904054234785316047107788488299468939839601,0051,0741,0001,063000
       Goodwill 
0
0
0
11,272
11,273
11,453
11,438
2,212
2,212
2,212
2,212
2,212
2,212
2,212
0
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
2,212
0
2,212
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000002,21202,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,2122,21202,2122,2122,2122,2122,2122,2122,21211,43811,45311,27311,272000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,675
5,878
5,742
5,716
5,490
5,765
37,706
37,693
25,431
15,858
3,434
3,468
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000003,4683,43415,85825,43137,69337,7065,7655,4905,7165,7425,8785,6750000000000000000000000000000000
       Intangible Assets 
0
0
0
30,503
30,401
32,295
31,997
31,886
31,774
31,663
31,551
27,725
27,646
27,543
0
27,369
27,255
27,147
27,030
26,958
35,562
35,458
35,428
36,165
36,031
35,899
35,768
33,501
33,486
33,515
33,519
33,555
33,580
34,789
34,760
34,080
34,064
34,042
34,019
34,013
33,990
33,505
33,493
33,491
0
33,472
0
31,632
0
31,613
0
30,115
0
30,104
9,747
9,747
0
9,976
9,853
9,853
9,8539,8539,97609,7479,74730,104030,115031,613031,632033,472033,49133,49333,50533,99034,01334,01934,04234,06434,08034,76034,78933,58033,55533,51933,51533,48633,50135,76835,89936,03136,16535,42835,45835,56226,95827,03027,14727,25527,369027,54327,64627,72531,55131,66331,77431,88631,99732,29530,40130,503000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,977
1,839
1,898
1,956
2,484
1,131
1,185
1,235
1,477
287
3,547
3,723
3,517
0
3,405
287
287
0
1
287
287
0
287
287
0
0
287
0
0
00287002872870287287102872873,40503,5173,7233,5472871,4771,2351,1851,1312,4841,9561,8981,8392,9770000000000000000000000000000000
> Total Liabilities 
0
0
0
13,850
11,369
10,501
17,110
17,403
9,082
5,736
5,452
5,360
3,945
16,635
16,746
17,040
17,265
16,166
15,208
16,379
20,753
19,793
19,775
22,212
23,871
21,362
23,960
23,543
21,983
18,025
33,121
33,123
30,863
29,464
25,814
25,770
25,052
29,247
29,046
22,165
26,064
30,379
31,611
27,392
0
23,760
0
21,596
0
17,419
0
14,654
0
17,357
14,651
14,651
0
11,989
10,650
10,650
10,65010,65011,989014,65114,65117,357014,654017,419021,596023,760027,39231,61130,37926,06422,16529,04629,24725,05225,77025,81429,46430,86333,12333,12118,02521,98323,54323,96021,36223,87122,21219,77519,79320,75316,37915,20816,16617,26517,04016,74616,6353,9455,3605,4525,7369,08217,40317,11010,50111,36913,850000
   > Total Current Liabilities 
0
0
0
13,606
11,125
10,266
16,875
17,156
8,835
5,489
5,205
4,824
3,410
3,084
3,482
4,317
4,447
3,799
3,518
5,092
5,368
4,594
4,169
7,755
8,756
6,450
9,483
9,664
9,013
5,244
10,972
11,966
11,177
11,273
9,350
9,808
10,869
9,138
10,290
8,821
9,487
11,521
12,855
10,223
0
9,575
10,131
10,131
0
9,457
8,033
8,033
0
6,913
7,415
7,415
0
5,885
7,179
7,179
7,1797,1795,88507,4157,4156,91308,0338,0339,457010,13110,1319,575010,22312,85511,5219,4878,82110,2909,13810,8699,8089,35011,27311,17711,96610,9725,2449,0139,6649,4836,4508,7567,7554,1694,5945,3685,0923,5183,7994,4474,3173,4823,0843,4104,8245,2055,4898,83517,15616,87510,26611,12513,606000
       Short-term Debt 
0
0
0
0
0
636
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
189
192
196
199
202
206
1,704
213
593
560
2,363
741
754
702
685
809
766
1,112
763
0
822
0
0
0
820
0
0
0
725
0
980
0
908
0
914
91409080980072500082000082207631,1127668096857027547412,3635605932131,704206202199196192189000000000000000000063600000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
549
497
1,332
1,212
1,728
1,576
1,516
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,5161,5761,7281,2121,3324975490000000000000000000000000000000
       Accounts payable 
0
0
0
2,452
3,409
3,243
2,914
2,354
1,054
1,561
1,584
1,773
1,759
335
369
719
1,688
1,017
324
1,419
1,805
1,069
627
1,785
2,429
511
1,468
1,354
708
457
663
973
935
1,468
940
725
1,586
938
924
1,358
2,307
1,298
1,112
1,373
0
836
433
433
0
1,074
498
498
0
688
634
634
0
890
340
340
340340890063463468804984981,074043343383601,3731,1121,2982,3071,3589249381,5867259401,4689359736634577081,3541,4685112,4291,7856271,0691,8051,4193241,0171,6887193693351,7591,7731,5841,5611,0542,3542,9143,2433,4092,452000
       Other Current Liabilities 
0
0
0
11,154
7,716
7,023
13,961
14,802
7,781
3,928
3,621
3,051
1,651
2,749
3,113
3,598
2,759
2,782
3,194
3,673
3,563
3,525
3,542
5,970
6,327
5,750
7,823
8,114
8,106
4,585
10,103
9,289
10,029
9,212
7,850
6,720
8,542
7,446
8,664
6,778
6,371
9,457
10,631
3,177
0
2,634
8,536
8,536
0
2,036
4,841
4,841
0
5,500
6,781
4,093
0
1,079
6,839
2,729
2,7296,8391,07904,0936,7815,50004,8414,8412,03608,5368,5362,63403,17710,6319,4576,3716,7788,6647,4468,5426,7207,8509,21210,0299,28910,1034,5858,1068,1147,8235,7506,3275,9703,5423,5253,5633,6733,1942,7822,7593,5983,1132,7491,6513,0513,6213,9287,78114,80213,9617,0237,71611,154000
   > Long-term Liabilities 
0
0
0
244
244
235
235
247
247
247
247
536
535
13,551
13,264
12,723
12,818
12,367
11,690
11,287
15,385
15,199
15,606
14,457
15,115
14,912
14,477
13,879
12,970
12,781
22,149
21,157
19,686
18,191
16,464
15,962
14,183
20,109
18,756
13,344
16,577
18,858
18,756
17,169
0
14,185
0
0
0
7,962
0
0
0
10,444
0
7,236
0
6,104
3,471
3,471
3,4713,4716,10407,236010,4440007,96200014,185017,16918,75618,85816,57713,34418,75620,10914,18315,96216,46418,19119,68621,15722,14912,78112,97013,87914,47714,91215,11514,45715,60615,19915,38511,28711,69012,36712,81812,72313,26413,551535536247247247247235235244244000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,992
0
3,563
0
3,136
0
2,854
0
2,746
0
2,483
0
0
002,48302,74602,85403,13603,56303,99200000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,818
19,402
17,452
15,812
14,913
13,348
19,347
18,031
12,517
11,633
14,103
13,491
12,883
0
10,089
7,474
7,474
0
4,399
3,485
3,485
0
7,590
4,490
4,490
0
0
0
0
00004,4904,4907,59003,4853,4854,39907,4747,47410,089012,88313,49114,10311,63312,51718,03119,34713,34814,91315,81217,45219,40220,8180000000000000000000000000000000
> Total Stockholder Equity
0
0
0
51,873
51,553
55,665
49,792
40,798
57,307
54,671
54,940
47,932
45,600
47,999
45,529
44,215
41,000
40,987
38,869
36,276
37,994
37,382
49,428
49,071
45,857
53,294
91,770
89,988
88,112
87,574
82,054
78,592
74,974
90,359
89,063
86,167
82,810
109,390
104,945
107,425
102,154
91,225
85,775
81,823
0
69,342
0
53,154
0
49,456
0
44,816
0
59,142
37,027
37,027
37,027
30,188
21,066
21,066
21,06621,06630,18837,02737,02737,02759,142044,816049,456053,154069,342081,82385,77591,225102,154107,425104,945109,39082,81086,16789,06390,35974,97478,59282,05487,57488,11289,98891,77053,29445,85749,07149,42837,38237,99436,27638,86940,98741,00044,21545,52947,99945,60047,93254,94054,67157,30740,79849,79255,66551,55351,873000
   Common Stock
0
0
0
35,557
36,132
37,082
37,082
37,082
37,082
37,082
37,082
37,082
37,082
37,082
37,082
37,082
37,082
39,488
9,872
9,872
10,890
10,890
13,919
13,927
13,956
14,051
19,678
19,678
19,687
20,087
20,137
20,137
20,148
22,119
22,301
22,301
22,311
24,554
24,555
24,557
24,557
24,561
24,563
24,563
0
24,563
24,563
24,563
0
24,563
24,563
24,563
0
24,563
24,563
24,563
0
24,563
24,563
24,563
24,56324,56324,563024,56324,56324,563024,56324,56324,563024,56324,56324,563024,56324,56324,56124,55724,55724,55524,55422,31122,30122,30122,11920,14820,13720,13720,08719,68719,67819,67814,05113,95613,92713,91910,89010,8909,8729,87239,48837,08237,08237,08237,08237,08237,08237,08237,08237,08237,08237,08237,08236,13235,557000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-6,073
0
0
0
-5,898
0
0
0
-6,126
0
0
0
-6,322
0
0
0
-6,517
0
0
0
-6,826
0
0
0
-6,154
0
0
0
-6,453
0
0
0
-7,866
0
0
0
-9,401
0
0
0
0
0
0
0
0
0
0
0
2,540
37,027
2,480
482,693
2,448
2,448482,6932,48037,0272,54000000000000-9,401000-7,866000-6,453000-6,154000-6,826000-6,517000-6,322000-6,126000-5,898000-6,0730000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
478,137
478,275
0
478,570
0
478,937
0
479,280
0
479,588
0
479,763
0
479,938
0
480,763
0
0
00480,7630479,9380479,7630479,5880479,2800478,9370478,5700478,275478,137000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
331,545
332,985
337,106
336,141
342,887
336,338
336,320
336,533
343,565
337,613
337,697
337,644
349,935
343,867
343,831
373,401
379,733
376,155
376,340
388,160
394,526
388,438
398,221
435,511
442,965
435,641
433,717
433,471
439,970
433,865
451,071
452,813
459,268
452,998
481,032
481,502
489,421
481,959
479,638
479,890
489,487
0
480,140
480,292
480,292
0
482,259
481,937
481,937
0
482,344
482,478
479,938
0
480,128
0
480,245
480,2450480,1280479,938482,478482,3440481,937481,937482,2590480,292480,292480,1400489,487479,890479,638481,959489,421481,502481,032452,998459,268452,813451,071433,865439,970433,471433,717435,641442,965435,511398,221388,438394,526388,160376,340376,155379,733373,401343,831343,867349,935337,644337,697337,613343,565336,533336,320336,338342,887336,141337,106332,985331,545000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.